BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/3/2023 10:22:43 AM | Browse: 184 | Download: 647
 |
Received |
|
2023-03-20 14:48 |
|
Peer-Review Started |
|
2023-03-20 14:51 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-06-15 09:02 |
|
Revised |
|
2023-06-28 16:43 |
|
Second Decision |
|
2023-07-07 02:41 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2023-07-07 06:31 |
|
Articles in Press |
|
2023-07-07 06:31 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-07-28 07:59 |
|
Publish the Manuscript Online |
|
2023-08-03 10:22 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Pathological complete response to neoadjuvant alectinib in unresectable anaplastic lymphoma kinase positive non-small cell lung cancer: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Lu-Ming Wang, Peng Zhao, Xu-Qi Sun, Feng Yan and Qian Guo |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Qian Guo, MD, Doctor, Doctor, Department of Medical Oncology, The First People’s Hospital of Hangzhou Lin’an District, No. 548 Yijin Street, Jincheng Street, Hangzhou 311300, Zhejiang Province, China. gqwy2007@163.com |
| Key Words |
Alectinib; Anaplastic lymphoma kinase; Non-small cell lung cancer; Neoadjuvant therapy; Case report |
| Core Tip |
Whether neoadjuvant alectinib can serve as a conversion therapy in patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) remains unclear. We report the first case of ALK-positive stage IIIB NSCLC in which a pathological complete response was achieved after neoadjuvant alectinib therapy. Subsequently, left upper lobectomy with mediastinal lymphadenectomy was performed. Postoperatively, alectinib is being continued as adjuvant therapy with a recurrence-free survival of 29 mo as of date. This case report highlights the feasibility of alectinib as neoadjuvant therapy for unresectable ALK-positive locally advanced NSCLC. |
| Publish Date |
2023-08-03 10:22 |
| Citation |
Wang LM, Zhao P, Sun XQ, Yan F, Guo Q. Pathological complete response to neoadjuvant alectinib in unresectable anaplastic lymphoma kinase positive non-small cell lung cancer: A case report. World J Clin Cases 2023; 5322-5328 |
| URL |
https://www.wjgnet.com/2307-8960/full/v11/i22/5322.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v11.i22.5322 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
